글로벌 연구동향
방사선종양학
- 2021년 03월호
[Dis Colon Rectum.] Risk Stratification Using Neoadjuvant Rectal Score in the Era of Neoadjuvant Chemoradiotherapy: Validation With Long-term Outcome Data 선행 항암화학방사선를 받는 직장암에서 위험도 층화를 위한 스코어링 개발 및 검증서울의대 / 임유진, 지의규*
- 출처
- Dis Colon Rectum.
- 등재일
- 2021 Jan
- 저널이슈번호
- 64(1):60-70. doi: 10.1097/DCR.0000000000001777.
- 내용
Abstract
Background: Despite the widespread use of neoadjuvant chemoradiotherapy, there is no prognostic surrogate marker established in locally advanced rectal cancer.Objective: This study evaluated the role of neoadjuvant rectal score as a prognostic factor to stratify individual-level risks of survival and tumor recurrence.
Design: This is a retrospective study.
Settings: This study was conducted at the Seoul National University Hospital.
Patients: A total of 397 patients who underwent chemoradiotherapy plus total mesorectal excision were analyzed.
Interventions: There was no intervention.
Main outcome measures: Harrell C statistic and receiver operating characteristic analysis, as well as Cox regression analysis, were used to assess the prognostic strength.
Results: The low (<8), intermediate (8-16), and high (>16) neoadjuvant rectal score groups included 91 (23%), 208 (52%), and 98 patients (25%). A high neoadjuvant rectal score was independently associated with inferior overall survival and disease-free survival (p = 0.011 and 0.008). Regarding the prognostic models adjusted for neoadjuvant rectal score (I) and ypT/N stage (II), the c-index was higher in model I (0.799 and 0.787, p = 0.009 for overall survival; 0.752 and 0.743, p = 0.093 for disease-free survival). The predictive ability of the neoadjuvant rectal score was superior to tumor regression grade, ypT, and ypN in the receiver operating characteristic analyses (p < 0.05 for all). Adjuvant chemotherapy was associated with better overall and disease-free survival (p = 0.003 and 0.052) in the high neoadjuvant rectal score group.
Limitations: Potential selection bias attributed to the retrospective study design was a limitation.
Conclusions: We verified the applicability of the neoadjuvant rectal score to stratify the relapse risk at the individual level for patients with stage II/III rectal cancer undergoing neoadjuvant chemoradiotherapy. Additional studies are needed to validate the usability of neoadjuvant rectal score levels as a determinant of adjuvant strategy.
Affiliations
Yu Jin Lim 1 , Changhoon Song 2 , Seung Hyuck Jeon 3 , Kyubo Kim 4 , Eui Kyu Chie 3 5
1 Department of Radiation Oncology, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, Seoul, Republic of Korea.
2 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
3 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea.
4 Department of Radiation Oncology, Ewha University College of Medicine, Seoul, Republic of Korea.
5 Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Republic of Korea.
- 덧글달기
- 이전글 [Breast.] Outcome of radiotherapy for clinically overt metastasis to the internal mammary lymph node in patients receiving neoadjuvant chemotherapy and breast cancer surgery
- 다음글 [Int J Gynecol Cancer.] Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer
편집위원
직장암의 수술전 방사선치료 시 예후 예측의 surrogate marker로서 neoadjuvant rectal score(NAR)의 의의를 real world의 장기추적 관찰결과를 이용하여 분석한 논문으로, tumor regression grade, ypT, ypN에 비해 NAR의 예측력이 더 높았으며 high NAR 그룹에서 수술 후 항암화학요법은 생존율 향상과 관련이 있었다.
덧글달기닫기2021-03-08 10:33:15
등록